Team

Rupert is a chartered accountant, with specialities in structured finance and venture capital. He has spent the last 25 years founding and building businesses in the energy, information, finance, medical and media sectors at a multi-billion pound level. Rupert is a co-founder of Origin Sciences.

Stuart qualified as a Chartered Accountant at KPMG, and subsequently worked in the manufacturing sector – ultimately taking the role of CFO of a fully quoted company, leading 16 global acquisitions, and 4 green field start-ups – often in conjunction with Rupert Lywood (Chairman).

Ian Daniels is a Consultant Colorectal & General Surgeon based at the Royal Devon & Exeter Hospital. His research interests include the diagnosis and management of bowel cancer, surgery for locally advanced and recurrent bowel cancer. His research portfolio can be viewed on PubMed [Daniels I]. Outside of clinical work he is Honorary President of Colostomy UK and front row for Team Colostomy UK.

Mr. Jay Luo is the President & Partner of Dymon Asia Capital, a Singapore headquartered alternative asset management firm. Dymon Asia established a strategic partnership with Temasek, a Singapore-based investment company, in 2014. Previously, Jay was the Head of APAC for S.A.C. Capital Advisors.

A long-standing (over 40 years) medical device expert, with experience gained through several roles including Quality, Regulatory, Operations, Project Management and Research and Development. Previous employers have included Unilever, Siemens and Alere as well as other SMEs. Notably, whilst with Alere, Michael oversaw production of 90M+ OTC products.

Hugo is passionate about discovery, innovation and commercial conversion. He has worked in a diverse range of fields including scientific education (retail), healthcare (delivery), property (enviro-friendly and affordable), hospitality and latterly primary care investigative and diagnostic solutions (ongoing). Hugo is also the original designer of the Oricol™ device.

Belinda is a Senior Lecturer in Molecular Epidemiology and epigenetics at The Queen Mary University in London. She has a PhD in functional genomics and genetics. In addition to being the CSO of Origin Sciences, she is also working on CRUK sponsored studies looking at early detection of cancer using methylation biomarkers for Cervical, Prostate and Breast cancer. Specialities include genetics, genomics, NGS, cellular and molecular biology, inflammation and cancer.

A long-standing (over 40 years) medical device expert, with experience gained through several roles including Quality, Regulatory, Operations, Project Management and Research and Development. Previous employers have included Unilever, Siemens and Alere as well as other SMEs. Notably, whilst with Alere, Michael oversaw production of 90M+ OTC products.

Jenny supports the Origin team with a strong background in administration and excellent communication and organisation skills. Prior to joining Origin, Jenny was an Accounts Administrator with Vindis Sawston, a car dealership firm, where she worked for over ten years. During her time at Vindis Sawston, Jenny spent some time supporting a busy Sales team in an administrative capacity before moving to the Accounts role. Before this, Jenny worked for four years at AXA Insurance as a Team Administrator / Underwriter. Jenny is a qualified Nursery Nurse and spent two years at ABC Nursery before moving to a career in Administration and Office Management.

Alison has a broad experience in the development, validation and application of biomarker assays. In her previous research and development roles at Carclo Diagnostic Solutions and Genesis Diagnostics, Alison has worked with multiple assay formats including microfluidics and microarray, covering both point of care and diagnostic laboratory applications. Alison also has experience in quality control and technical support for in vitro diagnostic assays and previously worked as a Biomedical Scientist in Immunology at the Sheffield Teaching Hospitals. Alison has an MPhil in Molecular Physiology from the University of Sheffield and a BSc(Hons) in Pharmacology from the University of Leeds.

Umar’s background includes working in a research lab whilst also gaining extensive knowledge of clinical trials from various disciplines of research. He has worked in the NHS on academic studies and on commercial studies within the pharmaceutical industry. He has acquired experience in the following areas of research, Type 1 & Type 2 Diabetes, Alzheimer’s & Dementia, Oncology and currently, Gastrointestinal disease. His experience has made him versatile across different aspects of clinical trials working on both drug development and medical device trials.